Dan Skovronsky (via Purdue University)

Eli Lil­ly touts a 'con­stel­la­tion' of suc­cess­es with their PhII Alzheimer’s study — but dis­ap­point­ing fail­ures drag down shares

Eli Lil­ly’s re­search di­vi­sion whipped up con­sid­er­able fer­vor for its Phase II top-line read­out on its next-gen Alzheimer’s drug do­nanemab. But af­ter spelling out the …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.